Our study was specifically focused on pediatric patients with T1D using CGMs; hence, our findings may not be generalizable to other populations, such as adults with T1D or children with type 2 diabetes or to explore outcomes for patients with insulin pumps or automated insulin dosing systems. The gene discussed is INS; the disease is type 2 diabetes mellitus.